Clinical significance of peritumoral mast cells in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy

被引:2
|
作者
Saigusa, Susumu [1 ]
Tanaka, Koji [1 ]
Ohi, Masaki [1 ,2 ]
Ishino, Yoshito [1 ]
Yasuda, Hiromi [1 ]
Okugawa, Yoshinaga [1 ]
Toiyama, Yuji [1 ]
Inoue, Yasuhiro [1 ]
Uchida, Keiichi [1 ]
Mohri, Yasuhiko [1 ]
Kusunoki, Masato [1 ,2 ]
机构
[1] Mie Univ, Grad Sch Med, Dept Gastrointestinal & Pediat Surg, Tsu, Mie 5148507, Japan
[2] Mie Univ, Grad Sch Med, Div Reparat Med, Inst Life Sci, Tsu, Mie 5148507, Japan
关键词
Mast cell; Foxp3; CD8; Esophageal squamous cell carcinoma; Neoadjuvant chemoradiotherapy; PRIMARY COLORECTAL-CANCER; PREOPERATIVE CHEMORADIOTHERAPY; PROGNOSTIC-SIGNIFICANCE; TUMOR ANGIOGENESIS; SURVIVAL; CHEMOTHERAPY; DENSITY; MICROENVIRONMENT; IMMUNOGENICITY; RELEVANCE;
D O I
10.1007/s10388-012-0356-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Neoadjuvant chemoradiotherapy (CRT) followed by surgery is the standard approach for locally advanced esophageal cancer. Recently, the microenvironment (including the host immune response) after conventional chemo- and/or radiotherapy has been highlighted. The aim of this preliminary study was to evaluate peritumoral mast cells (MCs) in esophageal squamous cell carcinoma (ESCC) after neoadjuvant CRT. We obtained a total of twenty specimens from patients with ESCC who underwent neoadjuvant CRT (30-40 Gy; 5-fluorouracil plus cisplatin) followed by surgery. We evaluated the expression of tryptase by MCs, Foxp3 by regulatory T cells, CD8 by cytotoxic T cells, and microvessel density (MVD) using immunohistochemistry. We investigated the correlation between the sizes of these marker-positive cell populations surrounding residual tumor nests, MVD and CRP, and clinical outcome. Patients with a low number of peritumoral MCs more frequently had lymphatic invasion (P = 0.0191). There was no significant correlation among the sizes of the marker-positive cell populations. We observed a significant negative correlation between the number of MCs and preoperative CRP levels (P = 0.009). Low numbers of peritumoral MCs, high MVD, and a preoperative C-reactive protein of > 0.5 mg/dL were significantly associated with poor overall survival (MCs: P = 0.0239; MVD: P = 0.0317; CRP: P = 0.0395). Our results suggest that peritumoral MCs may be associated with prognosis in patients with ESCC after neoadjuvant CRT.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 50 条
  • [1] Clinical significance of peritumoral mast cells in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
    Susumu Saigusa
    Koji Tanaka
    Masaki Ohi
    Yoshito Ishino
    Hiromi Yasuda
    Yoshinaga Okugawa
    Yuji Toiyama
    Yasuhiro Inoue
    Keiichi Uchida
    Yasuhiko Mohri
    Masato Kusunoki
    [J]. Esophagus, 2013, 10 : 12 - 19
  • [2] Prognostic Significance of Lymphovascular Invasion in Patients with Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy
    Chen, Wei-Hsun
    Huang, Yen-Lin
    Chao, Yin-Kai
    Yeh, Chi-Ju
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Liu, Yun-Hen
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (01) : 338 - 343
  • [3] Prognostic Significance of Lymphovascular Invasion in Patients with Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy
    Wei-Hsun Chen
    Yen-Lin Huang
    Yin-Kai Chao
    Chi-Ju Yeh
    Hsien-Kun Chang
    Chen-Kan Tseng
    Yun-Hen Liu
    [J]. Annals of Surgical Oncology, 2015, 22 : 338 - 343
  • [4] Neoadjuvant Chemoradiotherapy for Clinical Stage II-III Esophageal Squamous Cell Carcinoma
    Saeki, Hiroshi
    Morita, Masaru
    Nakashima, Yuichiro
    Sonoda, Hideto
    Hashimoto, Kenkichi
    Egashira, Akinori
    Oki, Eiji
    Ohga, Takefumi
    Kakeji, Yoshihiro
    Maehara, Yoshihiko
    [J]. ANTICANCER RESEARCH, 2011, 31 (09) : 3073 - 3077
  • [5] Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
    Kawai, Takaharu
    Kochi, Mitsugu
    Fujii, Masashi
    Song, Keio
    Hagiwara, Ken
    Watanabe, Megumu
    Matsuno, Yoritaka
    Suda, Hiroshi
    Yagi, Renpei
    Takayama, Tadatoshi
    [J]. ANTICANCER RESEARCH, 2017, 37 (06) : 3301 - 3306
  • [6] Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma
    Nakashima, Yuichiro
    Saeki, Hiroshi
    Hu, Qingjiang
    Tsuda, Yasuo
    Hisamatsu, Yuichi
    Ando, Koji
    Oki, Eiji
    Maehara, Yoshihiko
    [J]. ANTICANCER RESEARCH, 2018, 38 (12) : 6809 - 6814
  • [7] Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
    Wen, Jing
    Fang, Shuogui
    Hu, Yi
    Xi, Mian
    Weng, Zelin
    Pan, Chuqing
    Luo, Kongjia
    Ling, Yihong
    Lai, Renchun
    Xie, Xiuying
    Lin, Xiaodan
    Lin, Ting
    Chen, Jiyang
    Liu, Qianwen
    Fu, Jianhua
    Yang, Hong
    [J]. EBIOMEDICINE, 2022, 86
  • [8] Surgery or Surveillance for Esophageal Squamous Cell Carcinoma With Clinical Complete Response After Neoadjuvant Chemoradiotherapy
    Ting, Ying-Che
    Hsu, Po-Kuei
    Chen, Hui-Shan
    Lin, Chih-Hung
    Chuang, Cheng-Yen
    Hsu, Han-Shui
    Hsu, Chung-Ping
    [J]. SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2023, 35 (03) : 603 - 614
  • [9] Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma
    Nagai, Yohei
    Yoshida, Naoya
    Baba, Yoshifumi
    Harada, Kazuto
    Imai, Katsunori
    Iwatsuki, Masaaki
    Karashima, Ryuichi
    Koga, Yuki
    Nomoto, Daichi
    Okadome, Kazuo
    Ishimoto, Takatsugu
    Imamura, Yu
    Watanabe, Masayuki
    Baba, Hideo
    [J]. DIGESTIVE ENDOSCOPY, 2020, 32 (01) : 39 - 48
  • [10] Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Akihiko Okamura
    Satoru Matsuda
    Shuhei Mayanagi
    Jun Kanamori
    Yu Imamura
    Tomoyuki Irino
    Hirofumi Kawakubo
    Shinji Mine
    Hiroya Takeuchi
    Yuko Kitagawa
    Masayuki Watanabe
    [J]. Annals of Surgical Oncology, 2021, 28 : 1209 - 1216